Fig. 7: Bubble plots illustrating the top enriched Reactome pathways (p.adj < 0.05) for each combination and gating logic.
From: Solubility based mechanistic profiling of combinatorial drug therapy
The top enriched pathways are shown for LS and RU combinations, as well as AND- and OR-gate targets, in these panels. Panel (A) shows the AND-gate (conjunction) results for LY3009120 and sapanisertib; panel (B) shows the OR-gate (disjunction) results for the same combination. Panel (C) shows the AND-gate results for ruxolitinib and ulixertinib, while panel (D) shows the OR-gate results for this combination. Within each panel, bubbles at “IN” represent pathways unique to intact (live) samples, “EXT” indicates pathways unique to extract (lysate) samples, and “IN_EXT” identifies pathways common to both. Bubble size corresponds to gene ratio (pathway genes / total tested), and color intensity reflects raw p-values (red = lower, blue = higher). Pathway names are truncated for clarity. Pathway enrichment analysis was performed using ReactomePA based on over-representation analysis. P-values were adjusted for multiple testing using the Benjamini–Hochberg method, and pathways with adjusted P < 0.05 were considered significant. Source data are provided as a Source Data File.
